Impact Factor
3.12
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.42
281 total citations
h5-index
23
h5 depth signal
Cited share
68.6%
81 of 118
Total citations
281
Citation footprint
Metric signal
2.06
External metric anchor
Self-citation
0.4%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
553
Canada
21
United Kingdom
18
Italy
18
Israel
11
Citing Fields of Research
Oncology
250
Immunology
141
Lymphomas
97
Prostate Cancer
53
Lung Cancer
51
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,948
Articles tracked across the journal lifetime
Indexed publication set
118
81 cited publications
Last 12 months
60
10.0 publications/month
Open access share
6.7%
4 OA publications in the last year
Leading citing country
United States
553 citing publications
Leading citing field
Oncology
250 citing publications
Latest tracked publication
1 September 2026
10 recent records available
Coverage & Indexing History
v6n2, Mar./Apr. 2000-
v6n2, Mar./Apr. 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Brain Imaging
Prostate Cancer
Lymphomas
Lung Cancer
Issuing & Sponsoring Bodies
Contributor
American Radium Society
Broad Categories
Neoplasms
Immunology
Health Education & Remote Healthcare
Prostate Cancer
Liver & Colon Cancer
Brain Imaging
Breast Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/ppo.0000000000000854
Open DOI
CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma
Chimeric antigen receptor (CAR) T cells have rapidly reshaped the treatment of relapsed and refractory multiple myeloma (MM), progressing from an experimental salvage option to a therapy with a demonstrated overall survival advantage and...
02
DOI 10.1097/ppo.0000000000000850
Open DOI
Tailoring Therapy for Frail and Elderly Myeloma Patients
Multiple myeloma is a plasma cell malignancy associated with heterogeneous clinical outcomes. The majority of patients are diagnosed during their seventh decade and often present with age-related comorbidities and organ dysfunction. Myel...
03
DOI 10.1097/ppo.0000000000000845
Open DOI
Monoclonal Antibodies and Antibody-Drug Conjugates
Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have significantly expanded the therapeutic landscape of multiple myeloma (MM), contributing to deeper and more durable responses and meaningful survival benefits across th...
04
DOI 10.1097/ppo.0000000000000853
Open DOI
Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant
The therapeutic goal in multiple myeloma (MM) is changing from long-term disease control to a potential cure. While anti-CD38-containing quadruplets have improved outcomes, relapses continue to occur in many patients. In recent years, ad...
05
DOI 10.1097/ppo.0000000000000846
Open DOI
Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass
Multiple myeloma has long been considered incurable; however, advances in therapy have markedly improved outcomes, with a growing proportion of patients achieving sustained remissions suggestive of cure. Minimal (or measurable) residual ...
06
DOI 10.1097/ppo.0000000000000849
Open DOI
Managing Novel CAR T-Cell Toxicities in Multiple Myeloma
B-cell maturation antigen (BCMA) targeted chimeric antigen receptor T-cell (CAR-T) cell therapy has proven highly efficacious for relapsed multiple myeloma, inducing deep and durable remissions. Recent reporting has bolstered significant...
07
DOI 10.1097/ppo.0000000000000848
Open DOI
Smoldering and Early Disease Interception
Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma characterized by marked heterogeneity in the risk of progression. Current management relies on clinical risk stratification to identify patients who might...
08
DOI 10.1097/ppo.0000000000000852
Open DOI
Proteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens
Multiple myeloma cells are uniquely dependent on proteostasis due to their exceptionally high immunoglobulin synthesis and protein turnover, rendering them hypersensitive to disruptions in protein degradation. Proteasome inhibitors targe...
09
DOI 10.1097/ppo.0000000000000851
Open DOI
Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma
Despite substantial improvements in survival over recent decades, multiple myeloma (MM) remains largely incurable, and most patients ultimately experience relapsed or refractory disease, highlighting the need for novel therapeutic strate...
10
DOI 10.1097/ppo.0000000000000847
Open DOI
T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity
Bispecific antibodies (BsAbs) bind simultaneously to an antigen on the surface of multiple myeloma (MM) cells and to CD3 on the surface of T cells. This engagement leads to T-cell activation and degranulation, releasing perforin and gran...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with 2024.
Supplements accompany some vols.
Also issued online.
Official journal of the American Radium Society.